The residues between the two transformation effector sites of Epstein- Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation

Journal of Virology

Volumn 73, Issue 12, 1999, Pages 9908-9916

  Izumi, Kenneth M ^a   McFarland, Ellen Cahir ^a   Riley, Elisabeth A ^a,c   Rizzo, Danielle ^a   Chen, Yuzhi ^a   Kieff, Elliott ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INTEGRATED DNA TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1;

ARTICLE; B LYMPHOCYTE; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS LATENCY;

EID: 0032750932     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.12.9908-9916.1999     Document Type: Article

References (77)

1. Baichwal, V. R., and B. Sugden. 1988. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461-467.
2. Brodeur, S. R., G. Cheng, D. Baltimore, and L. D. Thorley. 1997. Localization of the major NF-kB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J. Biol. Chem. 272:19777-19784.
3. Chen, W. G., Y. Y. Chen, M. M. Bacchi, C. E. Bacchi, M. Alvarenga, and L. M. Weiss. 1996. Genotyping of Epstein-Barr virus in Brazilian Burkitt's lymphoma and reactive lymphoid tissue. Type A with a high prevalence of deletions within the latent membrane protein gene. Am. J. Pathol. 148:17-23.
4. Cheng, G., and D. Baltimore. 1996. TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kB activation. Genes Dev. 10:963-973.
5. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 86:9558-9562.
6. Devergne, O., E. Hatzivassiliou, K. M. Izumi, K. M. Kaye, M. F. Kleijnen, E. Kieff, and G. Mosialos. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kB activation. Mol. Cell. Biol. 16:7098-7108.
7. Devergne, O., M. Hummel, H. Koeppen, M. Le Bean, E. C. Nathanson, E. Kieff, and M. Birkenbach. 1996. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Virol. 70:1143-1153.
8. Devergne, O., E. Cahir McFarland, G. Mosialos, K. M. Izumi, C. F. Ware, and E. Kieff. 1998. Role of the TRAF binding site and NF-kB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:7900-7908.
9. Dolcetti, R., P. Zancai, V. De Re, A. Gloghini, B. Bigoni, B. Pivetta, S. De Vita, A. Carbone, and M. Boiocchi. 1997. Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood 89:1723-1731.
10. Eliopoulos, A. G., S. M. S. Blake, J. E. Floettmann, M. Rowe, and L. S. Young. 1999. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73:1023-1035.
11. Eliopoulos, A. G., and L. S. Young. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742.
12. Fennewald, S., V. van Santen, and E. Kieff. 1984. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J. Virol. 51:411-419.
13. Gires, O., F. Kohlhuber, E. Kilger, M. Baumann, A. Kieser, C. Kaiser, R. Zeidler, B. Scheffer, M. Ueffing, and W. Hammerschmidt. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:3064-3073.
14. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340: 393-397.
15. Harada, S., R. Yalamanchili, and E. Kieff. 1998. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation. J. Virol. 72:9948-9954.
16. Hatzivassiliou, E., W. E. Miller, T. N. Raab, E. Kieff, and G. Mosialos. 1998. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J. Immunol. 160:1116-1121.
17. Hayashi, K., W. G. Chen, Y. Y. Chen, M. M. Bacchi, C. E. Bacchi, M. Alvarenga, E. S. Abreu, K. L. Chang, and L. M. Weiss. 1997. Deletion of Epstein-Barr virus latent membrane protein 1 gene in United States and Brazilian Hodgkin's disease and reactive lymphoid tissue: high frequency of a 30-bp deletion. Hum. Pathol. 28:1408-1414.
18. Hayashi, K., W. G. Chen, Y. Y. Chen, I. Murakami, H. L. Chen, N. Ohara, S. Nose, K. Hamaya, S. Matsui, M. M. Bacchi, C. E. Bacchi, K. L. Chang, and L. M. Weiss. 1998. Deletion of Epstein-Barr virus latent membrane protein 1 gene in Japanese and Brazilian gastric carcinomas, metastatic lesions, and reactive lymphocytes. Am. J. Pathol. 152:191-198.
19. Hu, L. F., E. R. Zabarovsky, F. Chen, S. L. Cao, I. Ernberg, G. Klein, and G. Winberg. 1991. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 72:2399-2409.
20. Huen, D. S., S. A. Henderson, C. D. Croom, and M. Rowe. 1995. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560.
21. Izumi, K. M., E. Cahir McFarland, A. T. Ting, E. A. Riley, B. Seed, and E. D. Kieff. 1999. The Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1) engages tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kB activation. Mol. Cell. Biol. 19:5759-5767.
22. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 94:1447-1452.
23. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1994. Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation. J. Virol. 68:4369-4376.
24. Izumi, K. M., and E. D. Kieff. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kB. Proc. Natl. Acad. Sci. USA 94:12592-12597.
25. Johnson, R. J., M. Stack, S. A. Hazlewood, M. Jones, C. G. Blackmore, L. F. Hu, and M. Rowe. 1998. The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J. Virol. 72:4038-4048.
26. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
27. Kaye, K. M., K. M. Izumi, H. Li, E. Johanssen, D. Davidson, R. Longnecker, and E. Kieff. 1999. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J. Virol. 73:10525-10530.
28. Kaye, K. M., K. M. Izumi, G. Mosialos, and E. Kieff. 1995. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J. Virol. 69:675-683.
29. Kershaw, G. R., C. Berger, C. McQuain, A. S. Al Homsi, G. Pihan, P. J. Quesenberry, B. A. Woda, and H. Knecht. 1997. Selective outgrowth of a posttransplant B-immunoblastic lymphoma expressing a latent membrane protein-1 deletion variant. Transplantation 64:1079-1081.
30. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2396. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. Straus (ed.), Virology, 3rd ed. Raven Press, Ltd., Philadelphia, Pa.
31. Kieff, E., and D. Liebowitz. 1990. Epstein-Barr virus and its replication, p. 1889-1920. In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsh, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Virology, 2nd ed. Raven Press, Ltd., New York, N.Y.
32. Kieser, A., E. Kilger, O. Gires, M. Ueffing, W. Kolch, and W. Hammerschmidt. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:6478-6485.
33. Kingma, D. W., W. B. Weiss, E. S. Jaffe, S. Kumar, K. Frekko, and M. Raffeld. 1996. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 88:242-251.
34. Knecht, H., E. Bachmann, P. Brousset, S. Rothenberger, H. Einsele, V. S. Lestou, G. Delsol, F. Bachmann, P. F. Ambros, and B. F. Odermatt. 1995. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10:523-528.
35. Lee, M.-A., M. E. Diamond, and J. L. Yates. 1999. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J. Virol. 73:2974-2982.
36. Li, S. N., Y. S. Chang, and S. T. Liu. 1996. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12:2129-2135.
37. Liebowitz, D., D. Wang, and E. Kieff. 1986. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58:233-237.
38. Mann, K. P., and D. Thorley-Lawson. 1987. Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. J. Virol. 61:2100-2108.
39. Mannick, J. B., J. I. Cohen, M. Birkenbach, A. Marchini, and E. Kieff. 1991. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J. Virol. 65:6826-6837.
40. Mehl, A. M., N. Fischer, M. Rowe, F. Hartmann, H. Daus, L. Trumper, M. Pfreundschuh, L. N. Muller, and F. A. Grasser. 1998. Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-virus (EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma. Int. J. Cancer 76:194-200.
41. Menezes, J., W. Liebold, G. Klein, and G. Clements. 1975. Establishment and characterization of an Epstein-Barr virus-(EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22:276-284.
42. Miller, G., J. Robinson, L. Heston, and M. Lipman. 1974. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc. Natl. Acad. Sci. USA 71:4006-4010.
43. Miller, G., T. Shope, H. Lisco, D. Stitt, and M. Lipman. 1972. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. USA 69:383-387.
44. Miller, W. E., G. Mosialos, E. Kieff, and N. Raab-Traub. 1997. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kB activation. J. Virol. 71:586-594.
45. Miller, W. E., J. L. Cheshire, A. S. Baldwin, and N. Raab-Traub. 1998. The NPC derived C15 LMP1 protein confers enhanced activation of NF-kB and induction of the EGFR in epithelial cells. Oncogene 16:1869-1877.
46. Miller, W. E., H. S. Earp, and N. Raab-Traub. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69:4390-4398.
47. Miller, W. E., R. H. Edwards, D. M. Walling, and N. Raab-Traub. 1994. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 75:2729-2740. (Erratum, 76:1305, 1995.)
48. Mitchell, T., and B. Sugden. 1995. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 69:2968-2976.
49. Moghaddam, A., M. Rosenzweig, P. D. Lee, B. Annis, R. P. Johnson, and F. Wang. 1997. An animal model for acute and persistent Epstein-Barr virus infection. Science 276:2030-2033.
50. Moorthy, R., and D. A. Thorley-Lawson. 1990. Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP. J. Virol. 64:829-837.
51. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J. Virol. 67:2637-2645.
52. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J. Virol. 67:1638-1646.
53. Mosialos, G., M. Birkenbach, R. Yalamanchili, T. VanArsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399.
54. Natkunam, Y., J. K. Elenitoba, D. W. Kingma, and O. W. Kamel. 1997. Epstein-Barr virus strain type and latent membrane protein 1 gene deletions in lymphomas in patients with rheumatic diseases. Arthritis Rheum. 40: 1152-1156.
55. Odermatt, B. F., P. U. Heitz, E. Bachmann, P. Brousset, K. Sandvej, and H. Knecht. 1994. Internal deletions of the latent membrane protein oncogenes of Epstein-Barr virus in Hodgkin's disease are almost identical with those of Asiatic nasopharyngeal carcinoma. Verh. Dtsch. Ges. Pathol. 78:324-328.
56. Quintanilla, M. L., M. C. Lome, F. Schwarzmann, E. Gradler, E. Reyes, A. A. Angeles, and F. Fend. 1998. Post-transplantation lymphoproliferative disorders in Mexico: an aggressive clonal disease associated with Epstein-Barr virus type A. Mod. Pathol. 11:200-208.
57. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. Straus (ed.), Virology, 3rd ed. Raven Press, Ltd., Philadelphia, Pa.
58. Robertson, E., and E. Kieff. 1995. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. J. Virol. 69:983-993.
59. Robertson, E. S., B. Tomkinson, and E. Kieff. 1994. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J. Virol. 68:1449-1458.
60. Rowe, M., M. Peng-Pilon, D. S. Huen, R. Hardy, D. Croom-Carter, E. Lundgren, and A. B. Rickinson. 1994. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kB activation and to induction of cell surface markers. J. Virol. 68:5602-5612.
61. Sandberg, M., W. Hammerschmidt, and B. Sugden. 1997. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J. Virol. 71:4649-4656.
62. Sandvej, K., J. W. Gratama, M. Munch, X. G. Zhou, R. L. Bolhuis, B. S. Andresen, N. Gregersen, and D. S. Hamilton. 1997. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood 90:323-330.
63. Sandvej, K., M. Munch, and S. Hamilton-Dutoit. 1996. Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice. J. Clin. Pathol. 49:M290-M297.
64. Sandvej, K., S. C. Peh, B. S. Andresen, and G. Pallesen. 1994. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 84:4053-4060.
65. Scheinfeld, A. G., R. G. Nador, E. Cesarman, A. Chadburn, and D. M. Knowles. 1997. Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am. J. Pathol. 151:805-312.
66. Shu, H. B., M. Takeuchi, and D. V. Goeddel. 1996. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc. Natl. Acad. Sci. USA 93:13973-13978.
67. Swaminathan, S., B. Tomkinson, and E. Kieff. 1991. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc. Natl. Acad. Sci. USA 88:1546-1550.
68. Takeshita, H., T. Yoshizaki, W. E. Miller, H. Sato, M. Furukawa, J. S. Pagano, and N. Raab-Traub. 1999. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J. Virol. 73:5548-5555.
69. Tao, Q., K. D. Robertson, A. Manns, A. Hildesheim, and R. F. Ambinder. 1998. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 91:1373-1381.
70. Tomkinson, B., and E. Kieff. 1992. Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J. Virol. 66:780-789.
71. Tomkinson, B., E. Robertson, and E. Kieff. 1993. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67:2014-2025.
72. Tomkinson, B., E. Robertson, R. Yalamanchili, R. Longnecker, and E. Kieff. 1993. Epstein-Barr virus recombinants from overlapping cosmid fragments. J. Virol. 67:7298-7306.
73. VanArsdale, T. L., S. L. VanArsdale, W. R. Force, B. N. Walter, G. Mosialos, E. Kieff, J. C. Reed, and C. F. Ware. 1997. Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kB. Proc. Natl. Acad. Sci. USA 94:2460-2465.
74. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
75. Wang, D., D. Liebowitz, and E. Kieff. 1988. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J. Virol. 62:2337-2346.
76. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:4173-4184.
77. Yalamanchili, R., S. Harada, and E. Kieff. 1996. The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation. J. Virol. 70:2468-2473.